Reports have shown that activation of tumor-specific CD4 + helper T (Th) cells is crucial for effective anti-tumor immunity and identification of Th-cell epitopes is critical for peptide vaccine-based cancer immunotherapy. Although computer algorithms are available to predict peptides with high binding affinity to a specific HLA class II molecule, the ability of those peptides to induce Th-cell responses must be evaluated. We have established HLA-DR4 (HLA-DRA*01:01/HLA-DRB1*04:05) transgenic mice (Tgm), since this HLA-DR allele is most frequent (13.6%) in Japanese population, to evaluate HLA-DR4-restricted Th-cell responses to tumor-associated antigen (TAA)-derived peptides predicted to bind to HLA-DR4. To avoid weak binding between mouse CD4 and HLA-DR4, Tgm were designed to express chimeric HLA-DR4/I-E 
Introduction
Tumor cells express various proteins different from those of normal somatic cells, or over-express proteins at higher levels than in normal cells. Thus, peptides derived from these proteins may be specifically recognized by T lymphocytes. Of the two tumor-specific T lymphocyte subsets, CD8 + cytotoxic T lymphocytes (CTL) recognize tumor-associated antigen (TAA)-derived peptides in the context of MHC class I molecules (MHC-I), whereas CD4 + helper T (Th) cells respond to peptide-MHC class II (MHC-II) complexes. Because of their ability to eradicate malignant cells directly, CTLs have long been defined as the critical effector cells in anti-tumor immunity, although Th cells can also induce robust anti-tumor immune responses [1] [2] [3] . It is well accepted that tumor-specific Th cells maintain the anti-tumor responses of CTLs by licensing dendritic cells (DC) to effectively prime CTLs [4, 5] by generating effective memory CTL [6, 7] , or by direct stimulation of effector CTLs [8] . Thus, identification and vaccination of Th-cell epitopes that activate tumor-specific Th cells is might be a promising method to induce effective anti-tumor immunity in tumor-bearing hosts. Although it may be possible to identify such Th-cell epitopes using human peripheral blood mononuclear cells (PBMCs) isolated from healthy donors or cancer patients, it requires frequent bleedings and assays using a large number of overlapping peptides, which is in many cases a very long and labor-intensive procedure.
Utilizing a computer algorithm for the prediction of peptides with high binding affinity to a specific HLA/MHC molecule might be a convenient alternative. For example, SYFPEITHI (http:// www.syfpeithi.de/) and BIMAS (http://www-bimas.cit.nih.gov) are powerful tools to predict MHC class I binding and therefore potential CTL-epitopes. On the other hand, the confidence of predicting peptides that bind to a specific HLA/MHC-II molecule is still under discussion and the ability of those peptides to induce Th-cell responses must be evaluated. Therefore, we established transgenic mice expressing HLA-DR4 (HLA-DRA/ HLA-DRB1*04:05). of which allele frequency is 13.6% in Japanese population, to evaluate HLA-DR4-restricted Th-cell responses to tumor-associated antigen (TAA)-derived peptides predicted to bind to HLA-DR4. Using those mice, immunization with peptides known to be recognized by HLA-DR4-restricted human Th cells successfully induced peptide-specific and HLA-DR4-restricted mouse Th cell responses, demonstrating the validity of the HLA-DR4 Tgm for the preliminary screening of novel TAA-derived and HLA-DR4-restricted Th epitopes, which could be clinically applicable for peptide vaccine-based cancer immunotherapy in the future.
Materials and Methods

Ethics Statement
This study was approved by the animal research committee of Kumamoto University (Permission Number: B25-115). The mice were maintained at the Center for Animal Resources and Development of Kumamoto University, and were handled in accordance with the animal care guidelines of Kumamoto University.
The Institutional Review Board of Kumamoto University approved the research protocol for collecting and using PBMCs from healthy donors performed in this study with written informed consent. 
Cell lines
L-DR4, genetically engineered mouse fibroblast L cells that express HLA-DR4 (HLA-DRA*01:01/DRB1*04:05), were maintained in DMEM supplemented with 10% fetal calf serum (FCS) and 50 U/ml penicillin/streptomycin in a 5% CO 2 atmosphere at 37°C.
Generation of bone marrow-derived dendritic cells
Bone marrow-derived dendritic cells (BM-DCs) were generated as described by Inaba et al [11] . Briefly, bone marrow cells obtained from mouse thighbones and hind limbs were cultured at 1 × 10 7 cells per well in 10 ml of RPMI 1640 supplemented with mouse GM-CSF 10 ng/ml, 10% FCS, 50 μM 2-mercaptoethanol (2ME) and 50 U/ml penicillin/ streptomycin. On day 14, the cells were recovered for antigen presentation.
CMV-egH 290-302 peptide (SYLKDSDFLDAAL) [12] , WT1-derived WT1 332-347 peptide (KRYFKLSHLQMHSRKH) [13] , CDCA1-derived CDCA1 55-78 peptide (IVYGIRLEHFYMMPVNSEVMYPHL) [14] , KIF20A -derived KIF20A 494-517 peptide (TLHVAKFSAIASQLVHAPPMQLGF) [15] , DEPDC1-derived DEPDC1 191-213 peptide (RYVILIYLQTILGVPSLEEVINP) and a negative control DEPDC1 60-85 peptide (NSNFGPEVTRQQTIQLLRKFLKNHVI). The purity of the peptides was routinely >95%. Lyophilized peptides were dissolved in DMSO and stored at −20°C.
Flow Cytometry
After hemolysis, PBMCs were stained with various PE-or FITC-conjugated mAbs. The cells were analyzed by FACScan (BD Biosciences, Franklin Lakes, NJ, USA) using Cell Quest software. PE-conjugated anti-HLA-DR-α-chain mAb L243 was from BD and FITC-conjugated anti-HLA-DR-β-chain mAb TAL15.1, PE-conjugated anti-I-A b mAb, PE-conjugated antimouse MHC-II mAb, FITC-conjugated anti-B220 mAb, PE-or FITC-conjugated anti-mouse CD4 mAb were from eBioscience (San Diego, CA, USA). 
Intracellular IFN-γ staining
Parental L-cells and L cells expressing HLA-DR4/I-E d were incubated with or without 10 μg/ml of WT1 332-347 peptide for 3 h, washed extensively, and then used as a stimulator. L cells were co-incubated with HLA-DR4-restricted WT1 332-347 peptidespecific CD4 + T cell clones [13] in the presence of 2 μg/ml CD28/CD49d Costimulatory Reagent (BD Biosciences) and 10 μg/ml Brefeldin A (Sigma-Aldrich, St Louis, MO, USA) for 5 h. Intracellular staining of IFN-γ was performed using BD Cytofix/ Cytoperm Buffer (BD Biosciences) according to the manufacturer's procedures after surface staining of CD4 molecules. PE-conjugated anti-IFN-γ mAb and FITCconjugated anti-CD4 mAb were from BD Biosciences. The cells were analyzed with FACSAria (BD Biosciences). The data were analyzed with FlowJo software.
Immunization of mice
Mice were primed either in the tail base with 50 μl of peptides in PBS (1 μg/μl) emulsified with 50 μl of Complete Freund's Adjuvant (CFA, Sigma-Aldrich) or by intravenous injection with peptide-pulsed BM-DCs (5 × 10 5 ). Seven days after the first immunization, mice were boosted with 50 μl of peptide in PBS (1 μg/μl) emulsified with 50 μl of Incomplete Freund's Adjuvant (IFA, Sigma-Aldrich) or CFA. On day 14, the inguinal lymph nodes or spleen cells were collected and cultured with the peptides and IL-2 (20 U/ml) for 7 days. Th cells were isolated by MACS beads (Miltenyi Biotec, Bergish-Gladbach, Germany) according to the manufacturer's instruction and assayed as described below. In some experiments, the harvested lymph nodes cells on day 14 were subjected to ex vivo proliferation assay.
T cell proliferation assay and blocking experiment
Purified Th cells were co-cultured with peptide-pulsed L-DR4 cells for 48 h in RPMI 1640 medium containing 8% FCS, 50 U/ml penicillin/streptomycin and 2ME, then pulsed with 1 μCi [ 3 H-] thymidine and cultured for another 17 h. The cells were harvested and incorporated radioactivity was counted using a scintillation counter (I450 Microbeta, Trilux, PerkinElmer). To confirm the HLA-DR4 restriction, single cell-suspension of inguinal LN cells was cultured with or without peptide in the presence or absence of anti-HLA-DR blocking mAb L243 for 48 h. Then, incorporated radioactivity was counted as described above.
IFN-γ ELISPOT assay
The ELISPOT assay was performed as described previously [14] . Briefly, Th cells were incubated in triplicate in ELISPOT plates (BD Biosciences) under the presence of the indicated peptides (10 μg/ml) and L-DR4 as antigen presenting cells. According to the manufacturer's instructions, the plates were incubated for 18 h at 37°C and IFN-γ-positive spots were quantified using Eli photo (Minerva Tech, Tokyo, Japan).
Generation of antigen-specific human CD4 + T cells
We obtained PBMCs from HLA-DR4-positive healthy donors (genotyped by the HLA Laboratory, Kyoto, Japan). Induction of antigen-specific CD4 + T cells was performed as follows:. We isolated the PBMCs from the heparinized blood of Japanese healthy donors by means of Ficoll-Conray density gradient centrifugation. CD4 + T cells and CD14 + cells were purified from PBMCs. Monocyte-derived DCs were generated from CD14 + cells and used as antigen-presenting cells (APCs) to induce antigen-specific CD4 + T cells. CD14 + cells co-cultured with human GM-CSF (100 ng/ml) and human IL-4 (10 ng/ml) in a 10 cm tissue culture dish for 7 days. On day 5, OK-432 (0.1 KE/ml) were added into the dish. On day 7, DCs (1 × 10 4 /well) were pulsed with 10 µg/ml peptide for 3 h, irradiated (45 Gy), and subsequently mixed with CD4 + T cells (3 × 10 4 /well) in 200 µL AIM-V (Life Technologies) supplemented with 5% human decomplemented plasma in each well of a 96-well, flatbottomed culture plate. After 7 days, half of the medium was removed from each culture, and fresh medium (100 µl/well) containing irradiated (50 Gy) autologous PBMCs (1 × 10 5 ) pulsed with peptide (10 µg/ml) and 5 ng/ml recombinant human IL-7 (rhIL-7) was added. Two days after the second stimulation with peptide, rhIL-2 was added to each well (10 IU/ml). A week later, the stimulated CD4 + T cells in each well were analyzed for specificity in IFN-γ ELISPOT assays. The T cells showing a specific response to the cognate peptide were transferred to 24-well plates and re-stimulated at weekly intervals with irradiated autologous PBMCs (1 × 10 6 /well) pulsed with the peptide in medium supplemented with rhIL-2 (20 IU/ml) and rhIL-7 (5 ng/ml) [14] . 
Results
Expression
Characterization of HLA-DR4 Transgenic Mice
To select HLA-DR-positive F 0 mice, their PBMCs were collected and analyzed by cell surface staining with anti-HLA-DR antibodies (anti-HLA-DRα mAb L243 and anti-HLA-DRβ mAb TAL15.1) by FACScan. Genomic DNA prepared from the cells was then subjected to PCR analysis 2 mice were positive for the expression of both HLA-DRα and -DRβ molecules 
Induction of HLA-DR4-restricted and non-self peptidespecific Th cells in Tgm
To check that Tgm could induce peptide-specific and HLA-DR4-restricted Th-cell responses, Tgm were immunized with a CMV-derived peptide, CMV-egH 290-302 ; SYLKDSDFLDAAL, that binds HLA-DR4 [12] using CFA and IFA as adjuvants. Th cells derived from immunized Tgm strongly proliferated when cocultured with CMV-egH 290-302 peptide-pulsed L-DR4 cells, but not with unpulsed cells (Figure 5A ). In addition, splenocytes isolated from immunized WT C57BL/6 mice did not respond to either peptide-pulsed or unpulsed L-DR4 cells. Therefore, Tgm immunized with HLA-DR4-binding CMV-derived peptides Induction of Th-cell responses specific for known HLA-DR4-binding TAA-derived peptides in Tgm Next, we determined whether immunization of Tgm with TAA-derived peptides could induce HLA-DR4-restricted peptide-specific mouse Th-cell responses. CDCA1 (cell division cycle associated 1) is a TAA frequently overexpressed in lung cancer, head-and-neck cancer and other malignancies [16, 17] . CDCA1 55-78 peptide (IVYGIRLEHFYMMPVNSEVMYPHL) is a CDCA1-derived peptide consisting of 15 amino acid residues (underlined) predicted to bind to HLA-DR4 with high affinity by a computer algorithm available at the Immune Epitope Data Base site (http://tools.immuneepitope.org/mhcii/). Tgm were immunized with CDCA1 55-78 peptide and CFA or IFA at the tail base as described in the Materials and Methods. As shown in Figure 5B the peptide. The data indicated that immunization of Tgm with TAA-derived peptides predicted to bind to HLA-DR4 successfully induced HLA-DR4-restricted and peptide-specific Th cells. As we previously reported [14] , the CDCA1 55-78 peptide is naturally processed from CDCA1 protein by dendritic cells to induce HLA-DR4-restricted Th-cell responses in human PBMCs isolated from HLA-DR4-positive healthy donors and cancer patients. Thus, the screening of TAA-derived HLA-DR4 binding Th-cell epitopes could be performed by the combination of computer algorithm analyses and peptide immunization of Tgm.
The human CDCA1 55-78 peptide is different from the mouse ortholog peptide at 3 amino acid residues (VYGIRLEHFYMMPVNSEVMYPHL vs VYGVRLEHFYMMPMNIEVTYPHL), and therefore CDCA1 peptide is non-self and may be immunogenic in mice. However, the WT1 332-347 peptide, a known HLA-DR4 binding human Thcell epitope derived from Wilms' Tumor 1 antigen (WT1) [13] , has an identical amino acid sequence with the mouse ortholog peptide. As expected, immunization of Tgm with WT1 332-347 peptide using CFA and IFA as adjuvants failed to induce Thcell responses (data not shown). DCs are superior antigen presenting cells and DC-based vaccination is thought to be a promising cancer immunotherapy [18] [19] [20] . Thus, to elicit stronger immune responses, we immunized Tgm with WT1 332-347 peptide-pulsed bone marrow-derived (BM)-DCs with a booster shot of WT1 332-347 peptide emulsified in CFA. In addition, to evaluate T-helper type 1 (Th1) cell-responses, which are important for the induction of potent anti-tumor immune responses [21] [22] [23] [24] , IFN-γ ELISPOT assay was performed to assess peptide-specific immune responses. As shown in Figure 5C , IFN-γ producing Th cells were increased in CD4 + cells stimulated with peptide-pulsed L-DR4 cells compared with those stimulated with unpulsed L-DR4 cells. Therefore, BM-DC-based peptide immunization of Tgm in combination with a th-cell assay using IFN-γ ELISPOT is an effective way to screen TAA-derived and HLA-DR4-restricted Th-cell epitopes, especially if the peptides has low immunogenicity.
Using BM-DC-based peptide immunization, we sought to identify the Th-cell epitope in KIF20A, which is frequently overexpressed in gastric cancer [25] , melanoma [26] , lung cancer, pancreatic cancer [27] , bladder cancer, breast cancer, and various other malignancies [28] , and thus is a promising target for cancer immunotherapy [29] . The 24-mer KIF20A 494-517 peptide (TLHVAKFSAIASQLVHAPPMQLGF) consisting of overlapping 15-mer peptides with relatively high affinity binding to HLA-DR4 was predicted by a computer algorithm. In our recent study in humans, the KIF20A 494-517 peptide induced HLA-DR4-restricted Th-cell responses from PBMCs of an HLA-DR4-positive healthy donor [15] .
To investigate the immunogenicity of the KIF20A 494-517 peptide in Tgm, mice were immunized with KIF20A 494-517 peptide-pulsed BM-DCs, and then with KIF20A 494-517 peptide in CFA emulsion. As shown in Figure 5D , Th-cells stimulated with KIF20A 494-517 peptide-pulsed L-DR4 cells showed a large number of IFN-γ positive spots compared with the Th-cells stimulated with unpulsed L-DR4.
Identification of a novel TAA-derived and HLA-DR4-restricted human Th-cell epitope using Tgm DEP domain containing 1 (DEPDC1) is a novel TAA classified as cancer-testis antigen that is significantly overexpressed in a majority of bladder cancer specimens [30, 31] . A clinical trial of DEPDC1-derived CTL epitopevaccination was performed in six patients with advanced bladder cancers [32] . Four patients achieved stable disease or partial responses with the induction of CTL responses to DEPDC1 294-302 9-mer peptide, while two cases were clinically non-responsive and negative for CTL responses. To induce more effective anti-tumor immune responses, we searched several candidate Th-cell epitope peptides in DEPDC1 using the computer algorithm and selected Figure 6B ). Thus, Tgm in combination with the computer algorithm-based analysis demonstrated its usefulness and effectiveness for the preliminary screening of HLA-DR4-restricted Th-cell epitopes.
Discussion
Many HLA class II Tgm have been established to identify Thcell epitopes [33, 34] , as well as to analyze the pathogenesis of autoimmune diseases when susceptibility is associated with particular HLA-II alleles. In these Tgm, HLA-II alleles expressed in Tgm are those frequent in Caucasians but not in Japanese. To screen TAA-derived Th-cell epitopes for peptidebased cancer immunotherapy in as many Japanese as possible, we generated HLA-DR4 Tgm expressing HLA- DRA*01:01/HLA*DRB1*04:05 genes of which allele frequency is 13.6% in the Japanese population, that is, about one forth of Japanese have this HLA-DR molecule.
Although the overall amino acid sequence homology between human and mouse CD4 is about 80%, homology of the extracellular domain is only 55% and therefore, interspecies interactions between HLA-DR4 and mouse CD4 could be a potential problem for the induction of HLA-DR4-restricted mouse Th cells. To avoid this, Tgm were generated to express chimeric HLA-DR4/I-E d molecules in which only the TCR-contacting and peptide-binding α1 and β1 domains were derived from HLA-DR4 but other-domains including CD4-interacting β2 domain were derived from I-E d . The chimeric HLA-DR4/I-E d molecules were successfully expressed on the CMV-egH 290-302 peptide is a cytomegalovirus envelope glycoprotein H (egH)-derived peptide reported to bind to HLA-DR4 and induced CMV-egH 290-302 peptide-specific Th-cell responses [12] . Thus, CMV-egH 290-302 peptide is a natural HLA-DR4 binding Th-cell epitope that could be used as a positive control to induce specific and HLA-DR4-restricted Th-cell responses in Tgm. and HLA-DR4 were interchangeable and that Tgm could be used for screening and identification of HLA-DR4-restricted Th-cell epitope peptides.
Since the CDCA1 55-78 peptide was predicted to be a strong HLA-DR4 binder but is a non-self peptide in mice, it was a good immunogenic peptide to induce mouse Th-cell responses in Tgm. A similar protocol to that used for CMV-egH 290-302 peptide immunization induced CDCA1 55-78 peptide-specific and HLA-DR4-restricted Th-cell responses. However, the WT1 332-347 peptide has an identical amino acid sequence to the mouse ortholog peptide, and immunization with CFA and IFA adjuvants was not successful, while immunization using peptide-pulsed DC was effective for the induction of peptidespecific and HLA-DR4-restricted Th-cell responses. Therefore, to screen the computer algorithm-predicted peptides that were expected to be less immunogenic for mice, the utilization of DCs prepared from syngeneic BM-DCs could be an alternative protocol for immunization. The KIF20A 494-517 peptide includes a 15-mer amino acid residue predicted to bind to HLA-DR4 with low affinity, and there are differences in three amino acid residues between the human peptide and mouse ortholog. However, the predicted core binding amino acid sequences to HLA-DR4 are similar between humans and mice (AKFSAIASQ vs AKFSALASQ), in which the only different amino acid residue, P6, is not in contact with the TCR but MHC-II. Thus, the KIF20A 494-517 peptide could be less immunogenic in mice to induce apparent Th-cell responses presented by HLA-DR4/I-E d . However, immunization of KIF20A 494-517 peptide -pulsed BMDCs followed by a booster shot using the same peptide in CFA emulsion successfully induced peptide-specific and HLA-DR4-restricted Th-cell responses. Therefore, the screening efficiency could be improved if peptide-pulsed DCs were used for immunization.
The DEPDC1 191-213 peptide has a different amino acid sequence to the mouse ortholog peptide (RYVILIYLQTILGVPSLEEVINP vs RYVIMIYLQTILSLPSIEELLNP), thus immunization using CFA and IFA as adjuvants was successful. DEPDC1 is overexpressed in various cancers, especially in bladder cancer and a clinical trial using DEPDC1-derived short CTL epitope peptide-vaccination was performed for 6 patients with advanced bladder cancer [30] [31] [32] , although the clinical response was marginal. In a mouse model, co-vaccination of CTL-and Th-epitope peptides from HER-2 increased the numbers of specific CTL and Th cells and decreased the number of regulatory T cells compared with CTL-epitope vaccination alone [35] . In other clinical trials, Slingluff and colleagues recently reported that combination of CTL epitopeand Th cell epitope-vaccination in melanoma patients induced clinical benefit compared with CTL epitope-vaccination alone [36] , and Woods and Cebon argued that tumor-specific T-cell help was associated with improved survival in melanoma [37] . Thus, co-vaccination of the DEPDC1 CTL peptide and Th epitope identified by using Tgm may induce additional or synergistic immune responses and clinical effects for bladder cancer patients.
In conclusion, the HLA-DR4 Tgm established in this study are useful for preliminary screening of HLA-DR4-restricted Thcell epitope peptides derived from TAAs among candidate peptides predicted to bind to HLA-DR4 by the computer algorithm. If the Th cells from Tgm immunized with TAA peptides were reactive to syngenic BM-DCs incorporated whole TAA protein, the screened peptides could be proven to be naturally processed and such experimental system could be a powerful tool for the identification of Th-cell epitope peptides that could be applicable for vaccines for cancer immunotherapy. 
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